Seattle Genetics and Takeda Pharmaceutical have received extended marketing authorisation from the European Commission (EC) for ADCETRIS (brentuximab vedotin) to treat CD30-positive cutaneous T-cell lymphoma (CTCL) in adults following at least one previous systemic therapy.

ADCETRIS is currently being studied in more than 70 clinical trials and formulated as an antibody-drug conjugate (ADC) to target CD30 expressed on the surface of several types of lymphoma cells.

The EC marketing authorisation covers the European Union (EU), Norway, Liechtenstein and Iceland.

Seattle Genetics president and CEO Clay Siegall said: “The approval of ADCETRIS for use in the European Union in CD30-positive CTCL patients represents a meaningful advance for patients with CTCL.

“The approval of ADCETRIS for use in the European Union in CD30-positive CTCL patients represents a meaningful advance for patients with CTCL.”

“Since ADCETRIS was first approved by the FDA in 2011, Seattle Genetics and Takeda have made significant progress in our goal to establish ADCETRIS as the foundation of care for CD30-expressing lymphomas, and we are working together on our next milestone of securing FDA approval and EU marketing authorisation for ADCETRIS’ use as a treatment for frontline advanced Hodgkin lymphoma.”

The EC reviewed findings from the Phase III ALCANZA trial that is reported to have met the primary endpoint with statistically significant improvement in the objective response rate using ADCETRIS.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Compared to 12.5% in the control arm, the objective response lasting at least four months (ORR4) was found to be 56.3% in the ADCETRIS arm.

The trial also demonstrated statistically significant key secondary endpoints such as complete response rate and progression-free survival with ADCETRIS.